HRP20140360T4 - K-ras mutacije i terapija anti-egfr antitijelom - Google Patents
K-ras mutacije i terapija anti-egfr antitijelom Download PDFInfo
- Publication number
- HRP20140360T4 HRP20140360T4 HRP20140360TT HRP20140360T HRP20140360T4 HR P20140360 T4 HRP20140360 T4 HR P20140360T4 HR P20140360T T HRP20140360T T HR P20140360TT HR P20140360 T HRP20140360 T HR P20140360T HR P20140360 T4 HRP20140360 T4 HR P20140360T4
- Authority
- HR
- Croatia
- Prior art keywords
- ras
- tumor
- ras mutation
- absence
- determining
- Prior art date
Links
- 101710113436 GTPase KRas Proteins 0.000 title claims 17
- 230000035772 mutation Effects 0.000 title claims 11
- 238000009175 antibody therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 238000000034 method Methods 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229960001972 panitumumab Drugs 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 102200006532 rs112445441 Human genes 0.000 claims 2
- 102200006531 rs121913529 Human genes 0.000 claims 2
- 102200006537 rs121913529 Human genes 0.000 claims 2
- 102200006539 rs121913529 Human genes 0.000 claims 2
- 102200006538 rs121913530 Human genes 0.000 claims 2
- 102200006541 rs121913530 Human genes 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (6)
1. In vitro postupak za predviđanje da li će pacijent koji pati od kolorektalnog adenokarcinoma biti neresponzivan na tretman sa panitumumabom, naznačen time što sadrži određivanje prisustva ili odsustva K-ras mutacije u tumoru navedenog pacijenta, pri čemu je K-ras mutacija izabrana od G12S, G12V, G12D, G12A, G12C i G13D; i pri čemu ako je K-ras mutacija prisutna, pacijent je predviđen da bude neresponzivan na tretman sa panitumumabom.
2. In vitro postupak prema patentnom zahtjevu 1, naznačen time što korak određivanja prisustva ili odsustva K-ras mutacije u tumoru sadrži amplifikaciju nukleinske kiseline K-ras iz tumora i sekvenciranje amplificirane nukleinske kiseline.
3. In vitro postupak prema patentnom zahtjevu 1, naznačen time što korak određivanja prisustva ili odsustva K-ras mutacije u tumoru sadrži detekciju mutantnog K-ras polipeptida u uzorku tumora uporabom specifičnog vezivnog sredstva za mutantni K-ras polipeptid.
4. Postupak za predviđanje da li će tumor iz kolorektalnog adenokarcinoma biti neresponzivan na tretman sa panitumumabom, naznačen time što sadrži određivanje prisustva ili odsustva K-ras mutacije u uzorku navedenog tumora, pri čemu je K-ras mutacija izabrana od G12S, G12V, G12D, G12A, G12C i G13D; i pri čemu prisustvo K-ras mutacije ukazuje na to da će tumor biti neresponzivan na tretman sa panitumumabom.
5. Postupak prema patentnom zahtjevu 4, naznačen time što korak određivanja prisustva ili odsustva K-ras mutacije u uzorku navedenog tumora sadrži amplifikaciju nukleinske kiseline K-ras iz tumora i sekvenciranje amplificirane nukleinske kiseline.
6. Postupak prema patentnom zahtjevu 4, naznačen time što korak određivanja prisustva ili odsustva K-ras mutacije u uzorku navedenog tumora sadrži detekciju mutantnog K-ras polipeptida uporabom specifičnog vezivnog sredstva za mutantni K-ras polipeptid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90694307P | 2007-03-13 | 2007-03-13 | |
| EP08742061.8A EP2121989B2 (en) | 2007-03-13 | 2008-03-11 | K-ras mutations and anti-egfr antibody therapy |
| PCT/US2008/003312 WO2008112269A2 (en) | 2007-03-13 | 2008-03-11 | K-ras mutations and anti-egfr antibody therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20140360T1 HRP20140360T1 (en) | 2014-05-23 |
| HRP20140360T4 true HRP20140360T4 (hr) | 2022-06-10 |
Family
ID=39689242
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140360TT HRP20140360T4 (hr) | 2007-03-13 | 2008-03-11 | K-ras mutacije i terapija anti-egfr antitijelom |
| HRP20171509TT HRP20171509T1 (hr) | 2007-03-13 | 2017-10-09 | K-ras mutacije i terapija anti-egfr antitijelom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171509TT HRP20171509T1 (hr) | 2007-03-13 | 2017-10-09 | K-ras mutacije i terapija anti-egfr antitijelom |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20080293055A1 (hr) |
| EP (2) | EP2465950B1 (hr) |
| JP (1) | JP2010521153A (hr) |
| AR (1) | AR065687A1 (hr) |
| AU (1) | AU2008226803A1 (hr) |
| CA (1) | CA2680326A1 (hr) |
| CL (1) | CL2008000717A1 (hr) |
| CY (2) | CY1115333T1 (hr) |
| DK (2) | DK2465950T3 (hr) |
| ES (2) | ES2458626T5 (hr) |
| HR (2) | HRP20140360T4 (hr) |
| HU (1) | HUE033695T2 (hr) |
| LT (1) | LT2465950T (hr) |
| MX (1) | MX2009009787A (hr) |
| PE (1) | PE20081880A1 (hr) |
| PL (2) | PL2121989T5 (hr) |
| PT (2) | PT2465950T (hr) |
| RS (2) | RS53265B2 (hr) |
| SI (2) | SI2465950T1 (hr) |
| TW (1) | TW200902553A (hr) |
| WO (1) | WO2008112269A2 (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| CN103424541B (zh) | 2006-05-18 | 2018-01-30 | 分子压型学会股份有限公司 | 确定针对病状的个性化医疗介入的系统和方法 |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| SI2412828T1 (sl) * | 2007-03-13 | 2013-10-30 | Amgen Inc. | Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr |
| US8583380B2 (en) | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| CN102301002A (zh) | 2008-11-12 | 2011-12-28 | 卡里斯生命科学卢森堡控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
| US8502015B1 (en) | 2009-07-06 | 2013-08-06 | Transgenex Nanobiotech, Inc. | Method of inducing cancer |
| CN102115782B (zh) * | 2009-12-30 | 2014-06-18 | 北京雅康博生物科技有限公司 | 用于定量检测K-ras突变的试剂盒 |
| JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
| JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
| JP2013523178A (ja) * | 2010-04-12 | 2013-06-17 | レスポンス ジェネティクス，インコーポレイティド | Ｋｒａｓプライマーおよびプローブ |
| EP2619329B1 (en) | 2010-09-24 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
| AU2012239997A1 (en) | 2011-04-07 | 2013-10-17 | Amgen Inc. | Novel EGFR binding proteins |
| CA2855356A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| EP4036247B1 (en) | 2012-09-04 | 2024-04-10 | Guardant Health, Inc. | Methods to detect rare mutations and copy number variation |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| JP6520705B2 (ja) * | 2013-03-19 | 2019-05-29 | 凸版印刷株式会社 | Ｅｇｆｒ阻害剤感受性予測方法 |
| ES2660989T3 (es) | 2013-12-28 | 2018-03-27 | Guardant Health, Inc. | Métodos y sistemas para detectar variantes genéticas |
| WO2015175705A1 (en) * | 2014-05-13 | 2015-11-19 | Board Of Regents, The University Of Texas System | Gene mutations and copy number alterations of egfr, kras and met |
| EP3390668A4 (en) | 2015-12-17 | 2020-04-01 | Guardant Health, Inc. | METHODS OF DETERMINING THE NUMBER OF TUMOR GENE COPIES BY ACELLULAR DNA ANALYSIS |
| CN110357965A (zh) * | 2019-06-24 | 2019-10-22 | 浙江大学 | 一种突变型kras特异性抗体及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5470705A (en) | 1992-04-03 | 1995-11-28 | Applied Biosystems, Inc. | Probe composition containing a binding domain and polymer chain and methods of use |
| DE69322266T2 (de) | 1992-04-03 | 1999-06-02 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP1161563A2 (en) | 1999-03-15 | 2001-12-12 | PE Corporation (NY) | Probe/mobility modifier complexes for multiplex nucleic acid detection |
| EP1313880A2 (en) | 2000-05-30 | 2003-05-28 | PE Corporation (NY) | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| MXPA04011550A (es) | 2002-05-20 | 2005-02-17 | Abgenix Inc | Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico. |
| US20050164218A1 (en) | 2003-05-30 | 2005-07-28 | David Agus | Gene expression markers for response to EGFR inhibitor drugs |
| ES2741574T3 (es) | 2004-03-31 | 2020-02-11 | Massachusetts Gen Hospital | Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| US20060088871A1 (en) * | 2004-10-22 | 2006-04-27 | Finkelstein Sydney D | Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens |
| JP2008536493A (ja) | 2005-04-01 | 2008-09-11 | アムジエン・インコーポレーテツド | 上皮増殖因子受容体遺伝子のコピー数 |
| BRPI0610440A2 (pt) * | 2005-04-14 | 2010-06-22 | Merck Patent Gmbh | terapia com anticorpo anti-egfr baseada em um maior número de cópias do gene egfr em tecidos de tumores |
| JP2008546421A (ja) † | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | Ｅｇｆｒおよびｋｒａｓ変異 |
| US8703769B2 (en) * | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
| ATE520979T1 (de) | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| US7908091B2 (en) * | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| US8293501B2 (en) * | 2006-09-12 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for performing low background multiplex nucleic acid amplification reactions |
| SI2412828T1 (sl) * | 2007-03-13 | 2013-10-30 | Amgen Inc. | Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr |
-
2008
- 2008-03-11 PL PL08742061.8T patent/PL2121989T5/pl unknown
- 2008-03-11 AU AU2008226803A patent/AU2008226803A1/en not_active Abandoned
- 2008-03-11 TW TW097108519A patent/TW200902553A/zh unknown
- 2008-03-11 HU HUE12154109A patent/HUE033695T2/en unknown
- 2008-03-11 CL CL200800717A patent/CL2008000717A1/es unknown
- 2008-03-11 US US12/046,319 patent/US20080293055A1/en not_active Abandoned
- 2008-03-11 MX MX2009009787A patent/MX2009009787A/es active IP Right Grant
- 2008-03-11 PE PE2008000451A patent/PE20081880A1/es not_active Application Discontinuation
- 2008-03-11 DK DK12154109.8T patent/DK2465950T3/en active
- 2008-03-11 EP EP12154109.8A patent/EP2465950B1/en active Active
- 2008-03-11 RS RS20140187A patent/RS53265B2/sr unknown
- 2008-03-11 AR ARP080100995A patent/AR065687A1/es unknown
- 2008-03-11 EP EP08742061.8A patent/EP2121989B2/en active Active
- 2008-03-11 PL PL12154109T patent/PL2465950T3/pl unknown
- 2008-03-11 ES ES08742061T patent/ES2458626T5/es active Active
- 2008-03-11 SI SI200831873T patent/SI2465950T1/sl unknown
- 2008-03-11 SI SI200831191T patent/SI2121989T2/sl unknown
- 2008-03-11 PT PT121541098T patent/PT2465950T/pt unknown
- 2008-03-11 CA CA002680326A patent/CA2680326A1/en not_active Abandoned
- 2008-03-11 LT LTEP12154109.8T patent/LT2465950T/lt unknown
- 2008-03-11 HR HRP20140360TT patent/HRP20140360T4/hr unknown
- 2008-03-11 ES ES12154109.8T patent/ES2635051T3/es active Active
- 2008-03-11 DK DK08742061.8T patent/DK2121989T4/da active
- 2008-03-11 RS RS20170996A patent/RS56422B1/sr unknown
- 2008-03-11 JP JP2009553623A patent/JP2010521153A/ja active Pending
- 2008-03-11 PT PT87420618T patent/PT2121989E/pt unknown
- 2008-03-11 WO PCT/US2008/003312 patent/WO2008112269A2/en active Application Filing
-
2012
- 2012-06-14 US US13/523,174 patent/US10030270B2/en active Active
-
2014
- 2014-04-16 CY CY20141100291T patent/CY1115333T1/el unknown
-
2017
- 2017-07-25 CY CY20171100792T patent/CY1119112T1/el unknown
- 2017-10-09 HR HRP20171509TT patent/HRP20171509T1/hr unknown
-
2018
- 2018-06-21 US US16/014,056 patent/US11155876B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140360T4 (hr) | K-ras mutacije i terapija anti-egfr antitijelom | |
| HRP20130764T1 (hr) | Mutacije k-ras i b-raf i lijeäśenje anti-egfr antitijelima | |
| JP2010521154A5 (hr) | ||
| JP2010521153A5 (hr) | ||
| Loomans-Kropp et al. | Cancer prevention and screening: the next step in the era of precision medicine | |
| Bronkhorst et al. | The emerging role of cell-free DNA as a molecular marker for cancer management | |
| Ho et al. | A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma | |
| RU2012111231A (ru) | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK | |
| Thress et al. | EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291 | |
| Reichardt et al. | Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial | |
| Frank et al. | Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? | |
| Torphy et al. | Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma | |
| Okines et al. | Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials | |
| Seppälä et al. | Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response | |
| Elez et al. | Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer | |
| Pécuchet et al. | Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities | |
| Gajate et al. | Influence of KRAS p. G13D mutation in patients with metastatic colorectal cancer treated with cetuximab | |
| Feng et al. | High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non–small-cell lung Cancer | |
| D’Angelo et al. | Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center | |
| Maertens et al. | A collaborative model for accelerating the discovery and translation of cancer therapies | |
| Li et al. | Current status of ctDNA in precision oncology for hepatocellular carcinoma | |
| WO2007124309A3 (en) | Methods for detecting mutations in jak2 nucleic acid | |
| Toth et al. | Non–small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations | |
| Ye et al. | TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma Corrigendum in/10.3892/or. 2022.8411 | |
| BR112019001384A2 (pt) | teste de combinação para câncer colorretal |